1B contains the corrected term "Sf9" which was incorrectly typed as "sf-9" at two locations. Support for correction of this typographical error is found throughout the specification, including at page 21, line 24 ("Sf9 (*Sporodoptera frugiperda*)"); and page 21, line 25 ("Sf9 cells"). Thus, substitute Figures 1A, 1B and 2would not add new matter and their substitution into the specification is appropriate.

The amendments to the claims also do not add new matter. In particular, one of the amendments to claim 6 merely incorporates one of the diseases recited in claim 7 (IgE-mediated disease) into claim 6. The other amendment to claim 6, which recited that the antibody is free of significant agonistic activity, merely confirms the description of the antibody to what was deemed allowable in sister application, U.S. Serial No. 08/469,015, now U.S. Patent 6,004,552. Newly added claim 29, which recites that the antigen binding fragment is "selected from the group consisting of Fab, $F(ab)_2$ and Fv", is supported in the specification at page 7, line 14 ("fragments such as Fab, $F(ab)_2$, Fv and others which retain the antigen binding function of the antibody"). Newly added claim 30, which recites that the monoclonal antibody or the antigen binding fragment thereof is "humanized", is supported throughout the specification, including at page 7, lines 9 and 21-23 ("humanized antibodies").

For all these reasons, the amendments to the claims do not constitute new matter.

Respectfully submitted,

McANDREWS, HELD & MALLOY, LTD.

By: 

Donald J. Pochopien, Esq.
Registration No. 32,167
34th Floor
500 West Madison Street
Chicago, Illinois 60661
(312) 757-8133

Dated: September 18, 2001
J:\open\djp\chiron\uspto\0925009 Preliminary Amendment.doc